Value through Innovation03 August 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer


MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke


Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)


Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung


New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries


Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st


Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study


New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers


Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care


Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA


NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication


Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim


ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung


Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union


Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians


Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions


FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD


Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16